Specialty Pharmacy

Pharmacists play a key role when it comes to medication substitution, especially for interchangeable biosimilars where allowed by state law.

Zaltenibart could be an effective treatment option for C3 glomerulopathy as the most proximal inhibitor of the alternative pathway.

The call follows the FDA’s sudden removal of tirzepatide from the drug shortage list, preventing compounding pharmacies from providing the drug.

Congenital muscular dystrophy type 1a is a severe, early-onset condition that currently has no treatment, but MDL-101 may serve as a 1-time, durable treatment option.

Despite self-reported improvements in cognitive function, neuropsychological tests showed little differences between 2 patient groups.

The agency does not intend to take action against the plaintiffs for the violation of the Federal Food, Drug, and Cosmetic Act, including the compounding of tirzepatide.

The FDA previously accepted the biologic license application for CT-P13 as a subcutaneous formulation.

In April 2024, the FDA approved ustekinumab-aekn as a subcutaneous injection for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.

On the heels of Women Pharmacist Day on October 12, we highlight 3 female pharmacists who have followed unique career paths that help to drive innovation and change in the industry, beyond the retail pharmacy setting.

The story of pinksocks and the inspiring movement that they launched.

The gold standard of testing for food allergies is an oral food challenge test where patients consume the allergen, such as peanut extract, under supervision.

Behind The Script is a photo submission campaign designed to feature real pharmacists with candid, HIPAA-compliant photos to celebrate American Pharmacist Month.

In this interview for World Standards Week, Nakia Eldridge, PharmD, MPH, of US Pharmacopeia (USP), discusses USP's key achievements in 2024, while outlining the organization's 2025 goals.

The lawsuit alleges that the action was taken without the required notice and disputes the agency’s warning of “localized supply disruption,” while calling for more transparency.

Offering pharmacy professionals insights into the benefits, importance and challenges associated with switching patients to long-acting injectables to treat schizophrenia.

This approval marks the first and only anti-tissue factor pathway inhibitor approved in the US for the treatment hemophilia A or B, and the first approved hemophilia treatment to be administered via a pre-filled, auto-injector pen.

Results are promising, particularly because they represent the second clinical trial of a GLP-1 receptor agonist showing potential benefits for PD motor symptoms

The exemption allows more time for partners to adhere to enhanced distribution security requirements in the Food, Drug, & Cosmetics Act and prevents possible supply chain disruptions.

Ambulatory infusion centers can help reduce the cost of care for payers and patients and allow pharmacists to contribute to a positive treatment experience.

The regulatory action is based on a positive preliminary analysis of the VANTAGE trial.

Despite its importance, after graduating from pharmacy school, many pharmacists likely experience a decline in confidence in their ability to appropriately evaluate studies and interpret statistical findings.

The analysis assessed the feasibility of autologous transplantation of chemically-induced pluripotent stem cell-derived islets for type 1 diabetes.

Formularies have become one of the biggest barriers to realizing the cost-saving potential of biosimilars.

When considering the 3-stage framework, perhaps a greater emphasis on pre-treatment phase research could help identify some of the more individual traits used to better predict patient outcomes.

The treatment aims to reduce prolonged QTc interval in patients with long QT syndrome.

Currently, Danon disease has a poor prognosis and does not have any pharmaceutical therapeutics for treatment or management.

As American Pharmacists Month begins, Alan Corley talks the importance of pharmacists and the value of the profession personally and to the overall community.

In May 2024, the first biosimilars for aflibercept were approved, which included aflibercept-jbvf (Yesafili; Biocon Biologics), known as MYL-1701P.

Positive trial results laid the groundwork for the designation.

Treatment for primary coenzyme Q10 (CoQ10) deficiency can include high-dose oral CoQ10 supplementation, but not all patients respond to this treatment.